drugset / Trial / NCT00904943

Topiramate 25 mg Capsules Under Fed Conditions

NCT00904943

Phase 1 Completed 18 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to compare the rate and extent of absorption of topiramate 25 mg capsules (test) versus Topamax® (reference) administered as 2 25 mg capsules under fed conditions.

Timeline

Start
2002-06
Primary completion
2002-07
Completion
2002-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Topiramate Small molecule 50 mg

Indications

No indication recorded.